Island Pharmaceuticals Limited (ASX:ILA)

Island Pharmaceuticals Limited has secured all necessary regulatory and ethical approvals for the compassionate use of Galidesivir in treating patients during the Bundibugyo Ebola epidemic in Uganda. This is facilitated under the World Health Organization's MEURI framework, which allows emergency use of unregistered and investigational interventions during health crises. The initiative represents a major milestone as it combines real-world clinical data collection during an active outbreak with ongoing pivotal Marburg efficacy studies under the FDA Animal Rule. Galidesivir, a broad-spectrum antiviral, has shown efficacy against Ebola, Marburg, and other filoviruses in preclinical studies. This effort is non-dilutive for shareholders, as it is government-sponsored, with Island Pharmaceuticals providing only the drug supply. The initiative strengthens the company's position in outbreak response and potential commercial opportunities through government procurement and biodefense stockpiling.